• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NONO-TFE3 双重融合 FISH 检测作为 NONO-TFE3 肾细胞癌诊断工具的适用性。

The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.

机构信息

Department of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China.

Department of Urology, Drum Tower Clinical Medical School of Nanjing Medical University, Nanjing, Jiangsu, China.

出版信息

Sci Rep. 2020 Oct 1;10(1):16361. doi: 10.1038/s41598-020-73309-4.

DOI:10.1038/s41598-020-73309-4
PMID:33004995
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7530984/
Abstract

NONO-TFE3 RCC is a subtype of Xp11.2 translocation renal cell carcinoma (RCC). So far, only a small amount of NONO-TFE3 RCC have been reported owing to lack of effective diagnosis methods. Utilizing the novel dual-fusion fluorescence in situ hybridization (FISH) probe reported here, 5 cases of NONO-TFE3 RCC were identified and were ultimately confirmed by RT-PCR. Histopathology, all 5 cases were consisted by sheets of epithelial cells and papillary architecture. The cytoplasm was abundantly clear, and nucleoli was not prominent. Besides, the nuclear palisading, subnuclear vacuoles and psammoma bodies were identified. The most distinctive features were strong positive TFE3 staining but equivocal split signals of the TFE3 probe, which might lead to the misdiagnosis of Xp11.2 translocation RCC. The median age and median tumor size of the five patients were 41.2 years and 3.6 cm, respectively. A median following follow-up of 27 months showed moderate disease progression and prognosis in NONO-TFE3 RCC patients. In conclusion, the present study demonstrates the effectiveness and reliability of the NONO-TFE3 dual-fusion FISH probe for diagnosing NONO-TFE3 RCC. Suspected cases of Xp11.2 translocation RCC showing biphasic pattern, strong positive TFE3 staining, and equivocal split signals in the TFE3 FISH assay indicated a possibility of NONO-TFE3 RCC.

摘要

NONO-TFE3 RCC 是 Xp11.2 易位肾细胞癌(RCC)的一种亚型。由于缺乏有效的诊断方法,到目前为止,仅报道了少量的 NONO-TFE3 RCC。利用本研究报告的新型双融合荧光原位杂交(FISH)探针,鉴定了 5 例 NONO-TFE3 RCC,并最终通过 RT-PCR 得到证实。组织病理学上,所有 5 例均由片状上皮细胞和乳头状结构组成。细胞质丰富透明,核仁不明显。此外,还观察到核栅状、核下空泡和砂粒体。最显著的特征是 TFE3 染色强阳性,但 TFE3 探针的分裂信号不确定,这可能导致 Xp11.2 易位 RCC 的误诊。5 名患者的中位年龄和肿瘤大小分别为 41.2 岁和 3.6cm。中位随访 27 个月显示 NONO-TFE3 RCC 患者的疾病进展和预后中等。总之,本研究表明 NONO-TFE3 双融合 FISH 探针诊断 NONO-TFE3 RCC 的有效性和可靠性。疑似 Xp11.2 易位 RCC 表现为双相模式、TFE3 染色强阳性和 TFE3 FISH 检测中不确定的分裂信号,提示可能为 NONO-TFE3 RCC。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/d78ea5ad6335/41598_2020_73309_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/b57c595880e7/41598_2020_73309_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/7e77ed920df6/41598_2020_73309_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/c937a04a34f9/41598_2020_73309_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/ce4625afd43e/41598_2020_73309_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/6d59098ff40f/41598_2020_73309_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/b243ec2822db/41598_2020_73309_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/d78ea5ad6335/41598_2020_73309_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/b57c595880e7/41598_2020_73309_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/7e77ed920df6/41598_2020_73309_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/c937a04a34f9/41598_2020_73309_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/ce4625afd43e/41598_2020_73309_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/6d59098ff40f/41598_2020_73309_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/b243ec2822db/41598_2020_73309_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa64/7530984/d78ea5ad6335/41598_2020_73309_Fig7_HTML.jpg

相似文献

1
The suitability of NONO-TFE3 dual-fusion FISH assay as a diagnostic tool for NONO-TFE3 renal cell carcinoma.NONO-TFE3 双重融合 FISH 检测作为 NONO-TFE3 肾细胞癌诊断工具的适用性。
Sci Rep. 2020 Oct 1;10(1):16361. doi: 10.1038/s41598-020-73309-4.
2
[Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].[伴有涉及TFE3的基因融合的X染色体倒位相关肾细胞癌的临床病理特征]
Zhonghua Bing Li Xue Za Zhi. 2018 Aug 8;47(8):574-579. doi: 10.3760/cma.j.issn.0529-5807.2018.08.002.
3
Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.具有NONO-TFE3基因融合的Xp11.2易位性肾细胞癌:形态学、预后及检测TFE3基因重排中的潜在陷阱
Mod Pathol. 2017 Mar;30(3):416-426. doi: 10.1038/modpathol.2016.204. Epub 2016 Dec 9.
4
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.TFE3融合变异分析确定了Xp11易位性癌症之间特定的临床病理关联。
Am J Surg Pathol. 2016 Jun;40(6):723-37. doi: 10.1097/PAS.0000000000000631.
5
TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.TFE3 断裂分离 FISH 检测与 TFE3 或组织蛋白酶 K 免疫组化染色单独检测相比,对 Xp11.2 易位相关性肾细胞癌具有更高的敏感性:扩大形态学谱。
Am J Surg Pathol. 2013 Jun;37(6):804-15. doi: 10.1097/PAS.0b013e31827e17cb.
6
Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.Xp11.2 易位性肾肿瘤,具有 TFE3 重排相关肾细胞癌和 Xp11 易位性肾间叶肿瘤伴黑色素细胞分化特征,携带 NONO-TFE3 融合基因。
Pathol Res Pract. 2019 Sep;215(9):152521. doi: 10.1016/j.prp.2019.152521. Epub 2019 Jun 27.
7
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N-methyladenosine of PARP1 mRNA and downregulating PTEN.TRAF3IP2-AS1 低表达通过刺激 PARP1 mRNA 的 N-甲基腺苷化和下调 PTEN 促进 NONO-TFE3 易位肾细胞癌的进展。
J Hematol Oncol. 2021 Mar 19;14(1):46. doi: 10.1186/s13045-021-01059-5.
8
RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.RBM10-TFE3 肾细胞癌的特征为中心体旁倒位,断裂分离荧光原位杂交显示一致的紧密分裂信号:10 例研究及文献复习。
Histopathology. 2019 Aug;75(2):254-265. doi: 10.1111/his.13866. Epub 2019 Jun 25.
9
Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.新设计的断裂分离和ASPL-TFE3双融合荧光原位杂交检测法在诊断Xp11.2易位性肾细胞癌和ASPL-TFE3肾细胞癌中具有应用价值:一篇遵循STARD规范的文章
Medicine (Baltimore). 2015 May;94(19):e873. doi: 10.1097/MD.0000000000000873.
10
Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.在肾脏肿瘤咨询服务中使用 TFE3 断裂 FISH 检测。
Am J Surg Pathol. 2013 Aug;37(8):1150-63. doi: 10.1097/PAS.0b013e31828a69ae.

引用本文的文献

1
MiT/TFE Family Renal Cell Carcinoma.MiT/TFE 家族肾细胞癌。
Genes (Basel). 2023 Jan 5;14(1):151. doi: 10.3390/genes14010151.
2
Clinicopathological features and prognosis of TFE3-positive renal cell carcinoma.TFE3 阳性肾细胞癌的临床病理特征及预后
Front Oncol. 2022 Oct 6;12:1017425. doi: 10.3389/fonc.2022.1017425. eCollection 2022.

本文引用的文献

1
RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.Xp11 易位相关性癌症的 RNA 测序揭示了新的基因融合和独特的临床病理相关性。
Mod Pathol. 2018 Sep;31(9):1346-1360. doi: 10.1038/s41379-018-0051-5. Epub 2018 Apr 30.
2
Xp11 Translocation Renal Cell Carcinoma and the Mesenchymal Counterparts: An Evolving Concept with Novel Insights on Clinicopathologic Features, Prognosis, Treatment, and Classification.Xp11易位性肾细胞癌及其间叶性对应物:一个不断发展的概念,对临床病理特征、预后、治疗和分类有新见解
Crit Rev Oncog. 2017;22(5-6):481-497. doi: 10.1615/CritRevOncog.2017020558.
3
PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue.
PRCC-TFE3双融合荧光原位杂交检测:一种在石蜡包埋组织中识别PRCC-TFE3肾细胞癌的新方法。
PLoS One. 2017 Sep 26;12(9):e0185337. doi: 10.1371/journal.pone.0185337. eCollection 2017.
4
MicroRNA expression profiling of Xp11 renal cell carcinoma.Xp11肾细胞癌的微小RNA表达谱分析
Hum Pathol. 2017 Sep;67:18-29. doi: 10.1016/j.humpath.2017.03.011. Epub 2017 Apr 12.
5
RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH.RBM10-TFE3肾细胞癌:由于隐匿性染色体Xp11.2倒位导致TFE3荧光原位杂交假阴性,可能成为诊断陷阱。
Am J Surg Pathol. 2017 May;41(5):655-662. doi: 10.1097/PAS.0000000000000835.
6
Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.具有NONO-TFE3基因融合的Xp11.2易位性肾细胞癌:形态学、预后及检测TFE3基因重排中的潜在陷阱
Mod Pathol. 2017 Mar;30(3):416-426. doi: 10.1038/modpathol.2016.204. Epub 2016 Dec 9.
7
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Amog Xp11 Translocation Cancers.TFE3融合变异分析确定了Xp11易位性癌症中的特定临床病理关联。
Am J Surg Pathol. 2017 Jan;41(1):138-140. doi: 10.1097/PAS.0000000000000730.
8
Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.XP11.2易位/TFE3基因融合性肾细胞癌的临床特征:一项观察性研究的系统评价和荟萃分析
BMC Urol. 2016 Jul 11;16(1):40. doi: 10.1186/s12894-016-0154-6.
9
Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern.通过福尔马林固定石蜡包埋(FFPE)RNA测序鉴定出一种新的复发性倒位,该倒位在肾细胞癌中导致RBM10-TFE3融合,且具有微妙的TFE3断裂分离荧光原位杂交(FISH)模式。
Genes Chromosomes Cancer. 2016 Jun;55(6):541-8. doi: 10.1002/gcc.22356. Epub 2016 Apr 7.
10
TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.TFE3融合变异分析确定了Xp11易位性癌症之间特定的临床病理关联。
Am J Surg Pathol. 2016 Jun;40(6):723-37. doi: 10.1097/PAS.0000000000000631.